Patents by Inventor Clara Isabel Rodrigues Leandro
Clara Isabel Rodrigues Leandro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11672839Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains, and products and cocktails thereof, including F99/10, F110/10, F27/12, Psa_F83/13, Psa_F95/13, F391/08, Kle_F92/15, Kle_F105/15, Kle_F134/15, Kle_F141/15, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.Type: GrantFiled: December 4, 2017Date of Patent: June 13, 2023Assignees: TECHNECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA, TECNIFAR—INDUSTRIA TECNICA FARMACEUTICA, SAInventors: Sofia Valker Córte-Real, Miguel Ângelo Costa Garcia, Clara Isabel Rodrigues Leandro, Ana Raquel Martins Barbosa
-
Publication number: 20210187046Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains and cocktails thereof, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.Type: ApplicationFiled: December 18, 2020Publication date: June 24, 2021Applicants: TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA, TECNIFAR - INDUSTRIA TECNICA FARMACEUTICA, S.A.Inventors: Clara Isabel Rodrigues Leandro, Ana Raquel Martins Barbosa, Daniela Jones Dias, Ana Filipa Martins, Miguel Ângelo da Costa Garcia, Sofia Volker Côrte-Real
-
Publication number: 20190290709Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains, and products and cocktails thereof, including F99/10, F110/10, F27/12, Psa_F83/13, Psa_F95/13, F391/08, Kle_F92/15, Kle_F105/15, Kle_F134/15, Kle_F141/15, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.Type: ApplicationFiled: December 4, 2017Publication date: September 26, 2019Inventors: Sofia Valker Côrte-Real, Miguel Ângelo Costa Garcia, Clara Isabel Rodrigues Leandro, Ana Raquel Martins Barbosa
-
Patent number: 9962419Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular diabetic foot infections. More specifically, the present invention is directed to novel cocktails of bacteriophage strains F44/10, F1 25/10, F770/05, F510/08, F1 245/05, and/or variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including cutaneous ulcers associated with diabetic foot infections, caused by, e.g., Staphylococcus aureus, Pseudomonas aeruginosa, and/or Acinetobacter baumannii. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics, growth factors, or other standard, as well as non-standard, therapies for diabetic foot infections.Type: GrantFiled: March 19, 2013Date of Patent: May 8, 2018Assignee: Tecnifar—Industria Tecnica Farmaceutica, S.A. Technophage, Investigação E Desenvolvimento Em Biotecnologia, SAInventors: João João Duarte Alves Mendes, Clara Isabel Rodrigues Leandro, Sofia Volker Côrte-Real
-
Patent number: 9737579Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: GrantFiled: July 22, 2016Date of Patent: August 22, 2017Assignees: Technophage, Investigacao E Desenvolvimento Em Biotecnologia, SA, Tecnifar—Industria Tecnica Farmaceutica, S.A.Inventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Patent number: 9682110Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.Type: GrantFiled: September 11, 2015Date of Patent: June 20, 2017Assignees: Technophage, Investigação E Desenvolvimento Em Biotechnologia, SA, Tecnifar-Indústria Técnia Farmacêutica, S.AInventors: Miguel Angelo Da Costa Garcia, Carlos Jorge Sousa De Sao Jose, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marcal Da Silva, Sara Ferreira Llorente Grancho Lourenco
-
Publication number: 20160317590Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: ApplicationFiled: July 22, 2016Publication date: November 3, 2016Inventors: Miguel Ångelo DA COSTA GARCIA, Carlos Jorge SOUSA DE SÃO JOSÉ, Clara Isabel RODRIGUES LEANDRO, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel MARTINS BARBOSA
-
Patent number: 9399049Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: GrantFiled: November 17, 2015Date of Patent: July 26, 2016Assignees: Technophage, Investigacao E Desenvolvimento Em Biotecnologia, SA, Tecnifar-Industria Tecnica Farmaceutica, S.A.Inventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Publication number: 20160074446Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: ApplicationFiled: November 17, 2015Publication date: March 17, 2016Inventors: Miguel Ângelo DA COSTA GARCIA, Carlos Jorge SOUSA DE SÃO JOSÉ, Clara Isabel RODRIGUES LEANDRO, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel MARTINS BARBOSA
-
Publication number: 20160022747Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.Type: ApplicationFiled: September 11, 2015Publication date: January 28, 2016Inventors: Miguel Angelo Da Costa Garcia, Carlos Jorge Sousa De Sao Jose, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marcal Da Silva, Sara Ferreira Llorente Grancho Lourenco
-
Patent number: 9222077Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: GrantFiled: September 19, 2011Date of Patent: December 29, 2015Assignees: Tecnifar—Industria Tecnica Farmaceutica, S.A., Technophage, Investigacao E Desenvolveimento Em Biotecnologia, SAInventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Patent number: 9134312Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.Type: GrantFiled: February 5, 2010Date of Patent: September 15, 2015Assignees: Tecnifar—Industria Tecnica Farmaceutica, S.A., Technophage, Investigação E Desenvolvimento Em Biotecnologia, SAInventors: Miguel Ängelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Sara Ferreira Llorente Grancho Lourenço
-
Publication number: 20150150919Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular diabetic foot infections. More specifically, the present invention is directed to novel cocktails of bacteriophage strains F44/10, F1 25/10, F770/05, F510/08, F1 245/05, and/or variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including cutaneous ulcers associated with diabetic foot infections, caused by, e.g., Staphylococcus aureus, Pseudomonas aeruginosa, and/or Acinetobacter baumannii. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics, growth factors, or other standard, as well as non-standard, therapies for diabetic foot infections.Type: ApplicationFiled: March 19, 2013Publication date: June 4, 2015Inventors: Joào Joào Duarte Alves Mendes, Clara Isabel Rodrigues Leandro, Sofia Volker Còrte-Real
-
Publication number: 20140079671Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: ApplicationFiled: September 19, 2011Publication date: March 20, 2014Applicants: TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA, TECNIFAR-INDÚSTRIA TÉCNICA FARMACÊUTICA, S.A.Inventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Publication number: 20120052048Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.Type: ApplicationFiled: February 5, 2010Publication date: March 1, 2012Applicants: TECNIFAR-INDUSTRIA TECNICA FARMACEUTICA, S.A., TECHNOPHAGE INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA SAInventors: Miguel Ängelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Sara Ferreira Llorente Grancho Lourenço